Literature DB >> 27420643

MeCP2 Binding Cooperativity Inhibits DNA Modification-Specific Recognition.

Sergei Khrapunov1, Yisong Tao1, Huiyong Cheng1, Camille Padlan1, Richard Harris1, Aristea S Galanopoulou1, John M Greally1, Mark E Girvin1, Michael Brenowitz1.   

Abstract

Methyl-CpG binding protein 2 (MeCP2) is a multifunctional protein that guides neuronal development through its binding to DNA, recognition of sites of methyl-CpG (mCpG) DNA modification, and interaction with other regulatory proteins. Our study explores the relationship between mCpG and hydroxymethyl-CpG (hmCpG) recognition mediated by its mCpG binding domain (MBD) and binding cooperativity mediated by its C-terminal polypeptide. Previous study of the isolated MBD of MeCP2 documented an unusual mechanism by which ion uptake is required for discrimination of mCpG and hmCpG from CpG. MeCP2 binding cooperativity suppresses discrimination of modified DNA and is highly sensitive to both the total ion concentration and the type of counterions. Higher than physiological total ion concentrations completely suppress MeCP2 binding cooperativity, indicating a dominant electrostatic component to the interaction. Substitution of SO4(2-) for Cl(-) at physiological total ion concentrations also suppresses MeCP2 binding cooperativity, This effect is of particular note as the intracellular Cl(-) concentration changes during neuronal development. A related effect is that the protein-stabilizing solutes, TMAO and glutamate, reduce MeCP2 (but not isolated MBD) binding affinity by 2 orders of magnitude without affecting the apparent binding cooperativity. These observations suggest that polypeptide flexibility facilitates DNA binding by MeCP2. Consistent with this view, nuclear magnetic resonance (NMR) analyses show that ions have discrete effects on the structure of MeCP2, both MBD and the C-terminal domains. Notably, anion substitution results in changes in the NMR chemical shifts of residues, including some whose mutation causes the autism spectrum disorder Rett syndrome. Binding cooperativity makes MeCP2 an effective competitor with histone H1 for accessible DNA sites. The relationship between MeCP2 binding specificity and cooperativity is discussed in the context of chromatin binding, neuronal function, and neuronal development.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27420643      PMCID: PMC6532394          DOI: 10.1021/acs.biochem.6b00451

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  5 in total

1.  Expression, Purification, Characterization and Cellular Uptake of MeCP2 Variants.

Authors:  Alexander V Beribisky; Hannes Steinkellner; Sofia Geislberger; Anna Huber; Victoria Sarne; John Christodoulou; Franco Laccone
Journal:  Protein J       Date:  2022-05-12       Impact factor: 4.000

2.  Identification of Novel MeCP2 Cancer-Associated Target Genes and Post-Translational Modifications.

Authors:  Isabel Castro-Piedras; David Vartak; Monica Sharma; Somnath Pandey; Laura Casas; Deborah Molehin; Fahmida Rasha; Mohamed Fokar; Jacob Nichols; Sharilyn Almodovar; Rakhshanda Layeequr Rahman; Kevin Pruitt
Journal:  Front Oncol       Date:  2020-12-10       Impact factor: 6.244

3.  Absence of MeCP2 binding to non-methylated GT-rich sequences in vivo.

Authors:  John C Connelly; Justyna Cholewa-Waclaw; Shaun Webb; Verdiana Steccanella; Bartlomiej Waclaw; Adrian Bird
Journal:  Nucleic Acids Res       Date:  2020-04-17       Impact factor: 16.971

4.  In silico structural analysis of sequences containing 5-hydroxymethylcytosine reveals its potential as binding regulator for development, ageing and cancer-related transcription factors.

Authors:  Andigoni Malousi; Alexandra-Zoi Andreou; Sofia Kouidou
Journal:  Epigenetics       Date:  2020-09-02       Impact factor: 4.528

5.  DNA looping by two 5-methylcytosine-binding proteins quantified using nanofluidic devices.

Authors:  Ming Liu; Saeid Movahed; Saroj Dangi; Hai Pan; Parminder Kaur; Stephanie M Bilinovich; Edgar M Faison; Gage O Leighton; Hong Wang; David C Williams; Robert Riehn
Journal:  Epigenetics Chromatin       Date:  2020-03-16       Impact factor: 4.954

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.